Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CLPP | Q16740 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849686 | 0.84 | MKNK1 (0.48) | MKNK1LMNAC5AR1FAAHMEN1 | |
| SCHEMBL2845073 | 0.80 | MKNK1 (0.54) | MKNK1C5AR1FAAHMEN1KMT2A | |
| SCHEMBL2848557 | 0.79 | MKNK1 (0.52) | MKNK1FAAHCLPP | |
| SCHEMBL2848817 | 0.77 | TRPV1 (0.52) | LMNA | |
| SCHEMBL4872328 | 0.77 | MKNK1 (0.50) | MKNK1FAAH | |
| SCHEMBL12994717 | 0.75 | MKNK1 (0.52) | MKNK1C5AR1FAAHMEN1KMT2A | |
| SCHEMBL12994723 | 0.75 | MKNK1 (0.52) | MKNK1LMNAC5AR1FAAHMEN1 | |
| SCHEMBL2849767 | 0.75 | TRPV1 (0.59) | MKNK1FAAHCLPP | |
| SCHEMBL2849779 | 0.74 | FAAH (0.70) | MKNK1FAAH | |
| SCHEMBL16510168 | 0.74 | BRS3 (0.49) | MKNK1C5AR1MEN1KMT2ACLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885369-B1 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8859545-B2 | Tetrahydronaphthyridine and tetrahydropyrido[4,3-D]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases | EVOTEC AG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | RENOVIS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-7745451-B2 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | RENOVIS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1885369-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | MKNK1 3465/4885LMNA 763/4885C5AR1 280/4885 |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | OPRL1, OPRK1, IL1B | MKNK1 3334/4885LMNA 1051/4885C5AR1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.